Significant elevation of aqueous endothelin-1 in central retinal vein occlusion

Hae Min Kang; Md Hasanuzzaman; So Won Kim; Hyoung Jun Koh; Sung Chul Lee

doi:10.1371/journal.pone.0252530

Significant elevation of aqueous endothelin-1 in central retinal vein occlusion

PLoS One. 2021 Jun 2;16(6):e0252530. doi: 10.1371/journal.pone.0252530. eCollection 2021.

Authors

Hae Min Kang¹, Md Hasanuzzaman², So Won Kim², Hyoung Jun Koh³, Sung Chul Lee⁴

Affiliations

¹ Department of Ophthalmology, Catholic Kwandong University College of Medicine, International St. Mary's Hospital, Incheon, Republic of Korea.
² Department of Pharmacology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
³ Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Republic of Korea.
⁴ Department of Ophthalmology, Konyang University Hospital, Daejeon, Republic of Korea.

Abstract

Purpose: To investigate aqueous humor concentrations of endothelin-1 (ET-1) in patients with central retinal vein occlusion (CRVO) compared with patients with branch retinal vein occlusion (BRVO) and a normal control group.

Methods: A total 80 subjects were included in this prospective study, including 15 patients with CRVO, 20 patients with BRVO, and 45 patients who underwent cataract surgery and had no concomitant ocular disease. Aqueous humor levels of ET-1 were obtained before intravitreal bevacizumab injection (IVB) and after 1 month.

Results: At baseline, the mean aqueous ET-1 level was 12.7±3.6 pg/mL in the CRVO group, 8.0±2.3 pg/mL in the BRVO group, and 2.0±0.9 pg/mL in the control group (P<0.001). After IVB, the mean aqueous level of ET-1 was 3.4±1.9 pg/mL (0.5-6.9 pg/mL) in the CRVO group and 1.8±1.0 pg/mL (0.3-3.2 pg/mL) in the BRVO group (P = 0.008). The mean aqueous ET-1 level was significantly reduced in both the patients with CRVO and those with BRVO (P<0.001).

Conclusion: The mean aqueous humor ET-1 level was significant higher in the patients with CRVO than those with BRVO and in the control group. After IVB, the mean level was significantly reduced in both the patients with CRVO and those with BRVO.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Bevacizumab / therapeutic use
Endothelin-1 / metabolism*
Female
Humans
Macular Edema / metabolism
Male
Middle Aged
Prospective Studies
Retinal Vein Occlusion / drug therapy
Retinal Vein Occlusion / metabolism*
Visual Acuity / drug effects

Substances

Endothelin-1
Bevacizumab

Grants and funding

This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2018R1C1B5085620). This paper has not been presented at a scientific meeting. None of the authors have a proprietary interest in this work.